CARMAT Obtained Approval to Proceed with First Human Implantations of Its Total Artificial Heart
These institutions are the St Pierre University Hospital (Brussels, Belgium), the Silesian Center for Heart Disease (Zabrze, Poland), the Prince Sultan Cardiac Center (Riyadh, Saudi Arabia), and the University Medical Centre Ljubljana (Ljubljana, Slovenia).
All these institutions share excellence in surgical results and heart patient care, depth of patient recruitment and experience in innovative medical devices pre-market clinical trials.
In a common statement, Prof. Didier de Cannière, Chief of the Department of Cardiac Surgery at St Pierre University Hospital in Brussels, Belgium, Prof. Marian Zembala, Chairman, Department of Cardiac Surgery and Transplantation and Director of the Silesian Center for Heart Diseases in Zabrze, Poland, Prof. Borut Geršak, Head of the Department of Cardiovascular Surgery at the Ljubljana University Medical Centre, in Ljubljana, Slovenia, and Prof. Antonio Calafiore, Head of the Department of Adult Cardiac Surgery at Prince Sultan Cardiac Center in Riyadh, Saudi Arabia, declared: “We are very glad to share our experience and knowledge and thus contribute to this extraordinary project, as end-stage heart failure is indeed an international health issue. CARMAT’s bioprosthetic artificial heart could bring true innovation to the heart failure surgical community and we are looking forward to starting its implantation and to exploring its potential benefits for our patients.”
Prof. Alain Carpentier, co-founder and Scientific Director at CARMAT, comments: "I have been very pleased to learn that the leaders of these prestigious departments are willing to join us in the evaluation of the Carmat bioprosthesis. As recognized experts in the field, they will be able to appreciate first-hand the unique features and remarkable performances of this prosthesis."
Marcello Conviti, CEO of CARMAT, concludes: “The patient selection process and the training of the clinical teams are ongoing in these four countries, supported by our French proctors, Prof. Christian Latrémouille, Cardiac Surgeon at the Georges Pompidou European Hospital in Paris and Prof. Daniel Duveau, Medical Director of the Thorax Institute and of the Department of Thoracic and Vascular surgery at University Hospital in Nantes. Implantations could start shortly following the completion of the training. Carmat expects to receive additional approvals in a near future, potentially in France (ANSM approval) and in other countries.”
Published on : Thu, 16 May 2013
Print as PDF
Monitor vital signs of sensitive patients with reliable, smart and intuitive technology Not available in the US Sensitive patients, like neonates, require comfortable care. With transcutaneous monitoring, you can easily keep track of the oxygenation...
Get an complete overview of your POCT setup - from one dashboard Your point-of-care-testing setup probably involves many different types of devices from various manufacturers. Radiometer's AQURE point-of-care management system can give you an overview...
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d